Recent US COPD Medical Affairs Reputation News

AstraZeneca reported positive Phase III results for tozorakimab in COPD, with reduced moderate-to-severe exacerbations across smoking histories, eosinophil levels, and lung-function severity; regulatory submissions are anticipated.

The US COPD pipeline is expanding, with investigational approaches including DPP1 inhibition, twice-yearly biologics, antiviral therapy for rhinovirus-associated exacerbations, lung denervation, and allergen-directed omalizumab research.

The COPD-OMA study, supported by the American Lung Association and NIH, is evaluating whether omalizumab can reduce exacerbations in allergen-sensitive COPD patients.

Cipla received US approval for a generic Advair Diskus equivalent in all three strengths, increasing competition in inhaled COPD therapy.

Recent US treatment innovation has strengthened the reputations of companies providing evidence-led, biomarker-focused medical affairs support, while increasing scrutiny of comparative efficacy, patient selection, affordability, and real-world outcomes.

The 2026 GOLD update reportedly lowered the recommended age threshold for RSV vaccination to 50 years, reinforcing prevention and comorbidity management as important COPD medical-affairs themes.

Major established COPD products, including Trelegy Ellipta, Anoro Ellipta, Symbicort, Breo Ellipta, and Spiriva Respimat, are expected to face Medicare price negotiations in 2027, making value communication and access strategy increasingly important.